百奥泰(688177) - 2023 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2023 was ¥146,383,740.09, a decrease of 4.19% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2023 was -¥128,559,363.86, with a year-to-date net profit of -¥382,180,237.12[5]. - Basic and diluted earnings per share for Q3 2023 were both -¥0.31[9]. - The net profit for the third quarter of 2023 was -382,180,237.12 CNY, compared to -255,621,854.06 CNY in the same period of 2022, representing a year-over-year decline of approximately 49.4%[42]. - The company reported a total comprehensive income of -382,127,705.49 CNY for the third quarter, compared to -255,446,268.88 CNY in the previous year, indicating a decline of approximately 49.5%[45]. - The company reported a net profit of ¥461,050,213.90 for the first three quarters of 2023, compared to ¥381,785,964.28 in the same period of 2022, reflecting a growth of about 20.9%[36]. - Operating revenue for the first three quarters of 2023 reached CNY 461,050,213.90, a 21% increase compared to CNY 381,785,964.28 in the same period of 2022[66]. Research and Development - R&D expenses for Q3 2023 amounted to ¥190,027,538.46, an increase of 22.07% year-over-year, representing 129.81% of total revenue[9]. - The net profit attributable to shareholders for the year-to-date period decreased primarily due to increased R&D expenses compared to the previous year[15]. - The company is currently in the clinical research phase with multiple projects in Phase III clinical trials, leading to increased clinical trial and technical service costs[15]. - Research and development expenses surged to ¥609,935,344.48 from ¥422,090,457.76, a significant increase of approximately 44.5%[39]. - The company has indicated plans for market expansion and new product development, although specific details were not disclosed in the report[66]. Assets and Liabilities - Total assets as of the end of Q3 2023 were ¥2,333,501,593.23, reflecting a 7.05% increase from the end of the previous year[9]. - Total assets increased to ¥2,333,501,593.23, up from ¥2,179,736,935.85, representing a growth of approximately 7.0% year-over-year[34]. - Total liabilities increased to ¥1,108,374,083.64 from ¥572,481,720.77, marking an increase of around 93.5%[36]. - The company's total equity decreased to ¥1,225,127,509.59 from ¥1,607,255,215.08, a decline of approximately 23.7%[36]. - The company's equity decreased to CNY 1,226,100,255.71 from CNY 1,608,908,360.07, a decline of about 24%[59]. Cash Flow - Cash flow from operating activities for the year-to-date period was -¥358,146,180.10[9]. - The net cash flow from operating activities for the third quarter was -358,146,180.10 CNY, worsening from -266,574,644.11 CNY year-over-year[48]. - The net cash flow from operating activities for the first three quarters of 2023 was -¥358,448,480.50, compared to -¥266,915,083.43 in the first three quarters of 2022, indicating a worsening of approximately 34%[70]. - The total cash and cash equivalents at the end of the third quarter of 2023 amounted to ¥322,084,174.24, a significant increase from ¥153,525,975.32 at the end of the same period in 2022[71]. - The company generated 1,548,000,000.00 CNY from investment activities in the first nine months of 2023, down from 3,073,000,000.00 CNY in the same period of 2022[48]. - The net cash flow from investment activities for the first three quarters of 2023 was ¥140,077,438.28, a significant improvement from -¥379,822,726.81 in the first three quarters of 2022[71]. - The cash inflow from financing activities in the first three quarters of 2023 was ¥427,468,514.00, with a net cash flow of ¥396,822,894.07, compared to a net outflow of -¥32,422,859.82 in the same period of 2022[71]. Shareholder Information - The company reported a total of 8,376 common shareholders at the end of the reporting period[16]. - The top shareholder, Guangzhou Qixi Group Co., Ltd., holds 159,471,170 shares, representing 38.51% of the total shares outstanding[19]. - Therabio International Limited, another significant shareholder, owns 47,177,729 shares, accounting for 11.39% of the total shares[19]. - The company has engaged in securities lending, with 519,100 shares lent out, which is 0.13% of the total share capital[26]. Market and Strategic Focus - The company is exploring market expansion opportunities, as indicated by the involvement of various investment partnerships and funds[22]. - The report indicates that there are no new product launches or technological developments mentioned in the current quarter[29]. - There are no significant mergers or acquisitions reported in the current quarter[29].